Cancer
Can Adding Pembrolizumab to Chemotherapy Improve Outcomes for Early Triple-Negative Breast Cancer?
What Did the Research Discover? This study examined whether adding pembrolizumab (Keytruda), an immune checkpoint inhibitor, to standard chemotherapy before surgery could improve outcomes for patients with early-stage triple-negative breast cancer (TNBC). In this large phase 3 trial, 1,174 patients with stage II or III TNBC were randomly assigned